GlassScriptPhysician profile
Tracy T Meadows
NPI 1447523501
$471.36
in general payments reported to CMS, 2019-2025
10 companies · $14.17 in 2025
The $14.17 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $167 · 2023: $94.38 · 2024: $32.80 · 2025: $14.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $112.18 | 2021 | |
| Ucb, INC. | $106.99 | 2022-2023 | Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $66.20 | 2021-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $61.56 | 2022-2023 | Rexulti |
| Jazz Pharmaceuticals INC. | $31.08 | 2023 | |
| Indivior INC. | $28.77 | 2022 | |
| Neurocrine Biosciences, INC. | $23.45 | 2021 | |
| Alkermes, INC. | $14.41 | 2022 | |
| Medtronic, INC. | $14.17 | 2025 | Inceptiv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.